OTCMKTS:RDGL Vivos (RDGL) Stock Price, News & Analysis $0.11 -0.01 (-8.04%) As of 04/3/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestBuy This Stock About Vivos Stock (OTCMKTS:RDGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vivos alerts:Sign Up Key Stats Today's Range$0.11▼$0.1250-Day Range$0.11▼$0.1652-Week Range$0.06▼$0.26Volume512,482 shsAverage Volume981,288 shsMarket Capitalization$50.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewVivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.Read More… Remove Ads Vivos Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreRDGL MarketRank™: Vivos scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Vivos. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Vivos is -11.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vivos is -11.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Vivos' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of Vivos has been sold short.Short Interest Ratio / Days to CoverVivos has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos has recently decreased by 19.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVivos does not currently pay a dividend.Dividend GrowthVivos does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.02% of the float of Vivos has been sold short.Short Interest Ratio / Days to CoverVivos has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos has recently decreased by 19.87%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News SentimentN/A News SentimentVivos has a news sentiment score of 1.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.98 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vivos this week, compared to 0 articles on an average week.Search Interest2 people have searched for RDGL on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vivos insiders have not sold or bought any company stock.Percentage Held by Insiders18.50% of the stock of Vivos is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Vivos' insider trading history. Receive RDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos and its competitors with MarketBeat's FREE daily newsletter. Email Address RDGL Stock News HeadlinesVivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion PlansFebruary 4, 2025 | finance.yahoo.comVivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics NationwideDecember 27, 2024 | markets.businessinsider.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.April 4, 2025 | Stansberry Research (Ad)Vivos Inc.'s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics NationwideDecember 26, 2024 | globenewswire.comVivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical TrialDecember 23, 2024 | globenewswire.comVivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3November 14, 2024 | proactiveinvestors.comVivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTMOctober 18, 2024 | globenewswire.comVivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to ExoticsSeptember 30, 2024 | finance.yahoo.comSee More Headlines RDGL Stock Analysis - Frequently Asked Questions How have RDGL shares performed this year? Vivos' stock was trading at $0.1149 at the beginning of the year. Since then, RDGL stock has decreased by 3.4% and is now trading at $0.1110. View the best growth stocks for 2025 here. How do I buy shares of Vivos? Shares of RDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vivos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos investors own include MannKind (MNKD), Agenus (AGEN), APA (APA), Aphria (APHA), Bionano Genomics (BNGO), Churchill Capital Corp IV (CCIV) and Canopy Growth (CGC). Company Calendar Today4/03/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorFinance Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:RDGL CIK1449349 Webwww.radiogel.com Phone(509) 736-4000Fax509-736-4007Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,890,000.00 Net MarginsN/A Pretax Margin-12,345.83% Return on EquityN/A Return on Assets-197.34% Debt Debt-to-Equity RatioN/A Current Ratio25.48 Quick Ratio25.48 Sales & Book Value Annual Sales$20,000.00 Price / Sales2,516.23 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-5.55Miscellaneous Outstanding Shares453,374,000Free Float369,805,000Market Cap$50.32 million OptionableNot Optionable Beta0.89 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free Report This page (OTCMKTS:RDGL) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.